

Figure 1

Inhibition of Spleen Cell Proliferation by AVP YYY




Figure 2

AVP YYY Effect on the Proliferation of M12.4.1 Cells *in vitro*




Figure 3




Figure 4

10/508968

Table 1. Description of Cell Lines		
cell line	origin	
Raji	Burkitt's Lymphoma, B cell	
C32	amelanotic melanoma	
MCF-7	breast carcinoma	
T-47D	breast carcinoma	
DLD-1	colorectal adenocarcinoma	
HT-29	colorectal adenocarcinoma	
A-498	carcinoma, kidney	
ACHN	renal cell adenocarcinoma	
HL-60	acute promyelocytic leukemia	
K562	CML, bone marrow	
HepG2	hepatocellular carcinoma	
Vero	monkey kidney	
Raw264	mouse macrophage	
A549	carcinoma, lung	
U937	histiocytic lymphoma	
SK-MEL-5	malignant melanoma	
PANC-1	epithelioid carcinoma, pancreas	
KATO III	gastric carcinoma	
RBL	rat basophilic	
Jurkat	lymphoma, T cell	
HUT-78	lymphoma, T cell	
EL-4	mouse T cell lymphoma	
Daudi	Burkitt's lymphoma	
P815	mast cell mastocytoma (murine)	
U266	B cell plasmacytoma	
SH-SY5Y	neuroblastoma	
SK-N-MC	neuroepithelioma	
IMR-32	neuroblastoma	
Y79	retinoblastoma	
Wf12	spheroecystosis, B lymphoblast	
A20	reticulum cell carcinoma, B cell (murine)	

Figure 5

BEST AVAILABLE COPY

Cell line Proliferation Responses to Drug In Vitro





Figure 6

10/508968

Proliferation Response of Human Breast Cancer Cell Lines to Drug



Human Breast Cancer Cell Lines

	ER-Positive	EGF-Responsive
MCF-7	+	+
T-47D	+	+
HCC 70	+	+
HCC 1500	++	+
ZR-75-1	+	+
MDA-MB-231	+	+
HCC 1806	+	+
MDA-MB-468	+	+
HCC 1954	+	+
HCC 1569	+	+
AU-565	+	+
Hs578Bst	+	+

Figure 7